Skip to main content

IPSEN Value Stock - Dividend - Research Selection

Ipsen S.A

ISIN: FR0010259150, WKN: A0ESMG

Market price date: 21.01.2022
Market price: 82,52 EUR


Ipsen S.A Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 10-09-2021
Cash flow
Net operating cash flow 771.300.000
Capital Expenditures -140.700.000
Free cash flow 630.600.000
Balance sheet
Total Equity 2.119.100.000
Liabilities & Shareholders equity 4.317.200.000
Income statement
Net income 548.000.000
Eps (diluted) 6,570
Diluted shares outstanding 83.095.000
Net sales/revenue 2.686.100.000

Fundamental ratios calculated on: 21-01-2022

Ratios
Key figures 21-01-2022
Cash flow
P/C 8,89
   
P/FC 10,87
Balance sheet
ROI12,69
ROE49,09
Income statement
P/E12,56
Div. Yield1,21%
P/B3,24
P/S2,55


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolIPN.PA
Market Capitalization8.316.554.752,00 USD
CountryFrance
IndicesSTOXX EUROPE 600,MSCI World Index
SectorsPharmaceuticals
Raw Data SourceIFRS in Millionen EUR
Stock Split
Internetwww.ipsen.com


Description of the company

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. It offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. The company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. It offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. The company has agreements with Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, Schwabe, BAKX Therapeutics Inc., and Exicure. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy SA.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.ipsen.com


NEWS